Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells

Tarek M. Zikry, Samuel C. Wolff, Jolene S. Ranek, Harris M. Davis, Ander Naugle, Austin A. Whitman, Michael R. Kosorok, Philip M. Spanheimer, Jeremy E. PurvisbioRxiv 2023 · DOI

TL;DR

This paper investigates why some ER+/HER2- breast cancer cells resist palbociclib, a common cancer drug. They found that "fractional resistance" isn't due to genetic mutations but rather subtle, non-genetic differences in cell cycle regulators, allowing a subset of cells to "detour" through the cell cycle and escape treatment. This highlights the importance of cell cycle plasticity in drug resistance and suggests new therapeutic strategies.

What Problem Does This Paper Address?

Palbociclib, a CDK4/6 inhibitor, has significantly improved outcomes for patients with ER+/HER2- metastatic breast cancer. However, a portion of tumor cells often continues to divide despite treatment, a phenomenon termed "fractional resistance." This resistance is a major hurdle to long-term treatment success, and the precise percentage of resistant cells is a strong predictor of clinical outcome. While genetic mutations are a known cause of drug resistance, the mechanisms behind this fractional resistance in ER+/HER2- breast cancer remain unclear. This study aims to uncover the cellular mechanisms driving this resistance, hypothesizing that it arises from inherent cell-to-cell variability in core cell cycle regulators.

Methods

The researchers employed a multi-pronged approach:

  • Multiplex, Single-Cell Imaging (4i): This advanced technique allowed them to simultaneously measure the protein levels of 14 key cell cycle regulators in individual cells. This provides a high-resolution view of cellular states.
  • Computational Data Integration (TRANSACT): To compare data from a cell line model (T47D) and primary patient tumors, they used TRANSACT to create a shared "latent space," effectively aligning the complex proteomic data from different sources.
  • Nonlinear Dimensionality Reduction (PHATE): PHATE was used to visualize the high-dimensional single-cell data in a low-dimensional space, revealing the complex relationships and trajectories of cells through the cell cycle.
  • Trajectory Inference (Slingshot & TrAGEDy): These algorithms were used to reconstruct the "paths" individual cells take through the cell cycle, especially under drug treatment. Slingshot identifies potential cell lineages, while TrAGEDy aligns these trajectories across different conditions to enable direct comparison.
  • Logistic Regression: This statistical method was used to identify which cell cycle regulators were most predictive of a cell's response (treated vs. untreated) within different cell cycle phases.

Datasets

  • T47D Cell Line: A well-established ER+/HER2- breast cancer cell line was used as a model system.
  • Primary Human Breast Tumor Sample: A specimen from a patient with ER+/HER2- invasive lobular carcinoma was used to validate findings in a more clinically relevant context.

Key Insights and Ideas

  • Non-Genetic Basis of Resistance: The study strongly suggests that fractional resistance to palbociclib is driven by non-genetic, cell-to-cell differences in protein expression, rather than mutations. This is a crucial distinction for understanding and overcoming resistance.
  • Cell Cycle Plasticity as a Survival Mechanism: The research highlights that cells can exhibit "plasticity" in their cell cycle progression, taking alternative "paths" to escape drug-induced arrest. This flexibility is key to their survival.
  • Unexpected Regulator Roles: While some expected regulators (like CDK2 and E2F1) were implicated, the study also found unexpected shifts in other regulators (like Cdt1 and cyclin B1) in resistant cells, suggesting noncanonical mechanisms are at play.
  • Premature G1 Enrichment: Resistant cells showed premature enrichment of G1 regulators (E2F1, CDK2) and, surprisingly, the G2/M regulator cyclin B1 before cell cycle entry, hinting at a complex rewiring of cell cycle control.

Key Results

  • Fractional Resistance Observed: Both the T47D cell line and primary tumor cells showed a subset of cells that continued to proliferate despite palbociclib treatment, confirming fractional resistance.
  • CDK2 and E2F1 Upregulation: Proliferating resistant cells consistently showed elevated levels of CDK2 and E2F1, consistent with known resistance mechanisms involving cyclin E/CDK2 activity.
  • Cdt1 Downregulation: A novel finding was the reduced expression of Cdt1 in resistant cells, which is essential for DNA replication, suggesting potential replication stress.
  • Cyclin B1 Enrichment: Unexpectedly, cyclin B1 (a G2/M regulator) was enriched in resistant cells in G0 and G1 phases, suggesting it might play a role in facilitating drug escape through noncanonical pathways.
  • Distinct Cell Cycle Paths: Trajectory analysis visualized how palbociclib treatment alters cell cycle progression, creating alternative "paths" that allow some cells to evade arrest.

Limitations and Future Work

  • Model Limitations: While T47D is a good model, it may not perfectly reflect all primary tumor cell physiologies. The use of a single primary tumor sample also has limitations.
  • Future Directions: The authors suggest investigating whether fractionally resistant cells are more prone to replication stress and genetic mutation. They also propose exploring additional combination therapies that target these resistant subpopulations and developing precision therapeutic regimens based on individual tumor subpopulation drug sensitivities. Further research into the specific targetable drivers of these resistant paths is also warranted.

Summary updated

Abstract

ABSTRACT The CDK4/6 inhibitor palbociclib blocks cell cycle progression in ER+/HER2- breast tumor cells. Although these drugs have significantly improved patient outcomes in metastatic breast cancers, a small percentage of tumor cells continues to divide in the presence of palbociclib—a phenomenon we refer to as fractional resistance. It is critical to understand the cellular mechanisms underlying fractional resistance because the precise percentage of resistant cells in patient tissue is a strong predictor of clinical outcome. Here, we hypothesize that fractional resistance arises from cell-to-cell differences in core cell cycle regulators that allow a subset of cells to escape CDK4/6 inhibitor therapy. We used multiplex, single-cell imaging to identify fractionally resistant tumor cells both in a cell culture model of ER+/HER2- breast cancer as well as live primary tumor cells resected from a patient. We found that tumor cells capable of proliferating in the presence of palbociclib showed both expected (e.g., CDK2, E2F1) and unexpected (e.g., Cdt1, p21, cyclin B1) shifts in core cell cycle regulators. Notably, resistant cells in both tumor models showed premature enrichment of the G1 regulators E2F1 and CDK2 protein and, unexpectedly, the G2/M regulator cyclin B1 just before cell cycle entry, suggesting that resistant cells may use noncanonical mechanisms to overcome CDK4/6 inhibition. Using computational data integration and trajectory inference approaches, we show how plasticity in cell cycle regulators gives rise to alternate cell cycle “paths” that allow individual ER+/HER2- tumor cells to escape palbociclib treatment. Understanding drivers of cell cycle plasticity, and how to eliminate resistant cell cycle paths, could lead to improved cancer therapies targeting fractionally resistant cells to improve patient outcomes.
BibTeX
@misc{zikry2023cell,
  author = {Tarek M. Zikry and Samuel C. Wolff and Jolene S. Ranek and Harris M. Davis and Ander Naugle and Austin A. Whitman and Michael R. Kosorok and Philip M. Spanheimer and Jeremy E. Purvis},
  title = {{Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells}},
  year = {2023},
  doi = {10.1101/2023.05.22.541831},
  howpublished = {bioRxiv},
}
Figure